OR WAIT 15 SECS
© 2021 MJH Life Sciences and BioPharm International. All rights reserved.
© 2021 MJH Life Sciences™ and BioPharm International. All rights reserved.
Lois Atkins is a principal consultant, CMC regulatory affairs at Eli Lilly and Company
Regulatory flexibility can make continuous improvement possible.
First in a three-part series that discusses the complexities of QbD implementation in biotech product development.